Evolus (NASDAQ:EOLS – Get Free Report) and Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
90.7% of Evolus shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Evolus and Lifecore Biomedical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $316.49 million | 1.54 | -$51.64 million | ($0.52) | -14.17 |
| Lifecore Biomedical | $128.87 million | 1.87 | -$40.50 million | ($1.07) | -5.95 |
Lifecore Biomedical has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Evolus has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Profitability
This table compares Evolus and Lifecore Biomedical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -10.85% | N/A | -13.00% |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
Analyst Ratings
This is a summary of current ratings for Evolus and Lifecore Biomedical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| Lifecore Biomedical | 1 | 4 | 0 | 0 | 1.80 |
Evolus presently has a consensus target price of $14.50, suggesting a potential upside of 96.74%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 2.04%. Given Evolus’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Evolus is more favorable than Lifecore Biomedical.
Summary
Evolus beats Lifecore Biomedical on 9 of the 13 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
